An isolated or purified T-cell receptor (TCR) comprising: (a) SEQ ID NOs: 3-8 or (b) a functional variant of (a), wherein the TCR of (a) and the functional variant of (b) specifically bind to (i) MAGE A3 that is presented by HLA-DPβ1*04 and (ii) MAGE-A6, wherein the functional variant comprises: (I) SEQ ID NOs: 3, 4, 6, 7, 8, and 29, wherein: Xaa at 4 is Ala, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Ala in SEQ ID NO: 29; or Xaa at 4 is Val, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; or (II) SEQ ID NOs: 3, 4, 5, 6, 7, and 30, wherein: Xaa at 4 is Ala, Xaa at 5 is Thr, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30; or Xaa at 4 is Arg, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30, preferably wherein the functional variant comprises (a) SEQ ID NO: 29, wherein Xaa4 is Ala, Xaa5 is Ser, Xaa6 is Gly, and Xaa7 is Thr, or (b) SEQ ID NO: 29, wherein Xaa4 is Ser, Xaa5 is Ala, Xaa6 is Gly, and Xaa7 is Thr. (a) SEQ ID NOs: 3-8 or (b) a functional variant of (a), wherein the TCR of (a) and the functional variant of (b) specifically bind to (i) MAGE A3 that is presented by HLA-DPβ1*04 and (ii) MAGE-A6, wherein the functional variant comprises: (I) SEQ ID NOs: 3, 4, 6, 7, 8, and 29, wherein: Xaa at 4 is Ala, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Ala in SEQ ID NO: 29; or Xaa at 4 is Val, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; or (II) SEQ ID NOs: 3, 4, 5, 6, 7, and 30, wherein: Xaa at 4 is Ala, Xaa at 5 is Thr, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30; or Xaa at 4 is Arg, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30, (I) SEQ ID NOs: 3, 4, 6, 7, 8, and 29, wherein: Xaa at 4 is Ala, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Ala in SEQ ID NO: 29; or Xaa at 4 is Val, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; or Xaa at 4 is Ala, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; Xaa at 4 is Ser, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Ala in SEQ ID NO: 29; or Xaa at 4 is Val, Xaa at 5 is Ser, Xaa at 6 is Gly, and Xaa at 7 is Thr in SEQ ID NO: 29; or (II) SEQ ID NOs: 3, 4, 5, 6, 7, and 30, wherein: Xaa at 4 is Ala, Xaa at 5 is Thr, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30; or Xaa at 4 is Arg, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30, Xaa at 4 is Ala, Xaa at 5 is Thr, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30; or Xaa at 4 is Arg, Xaa at 5 is Ala, Xaa at 6 is Gly, and Xaa at 7 is Pro in SEQ ID NO: 30, (a) SEQ ID NO: 29, wherein Xaa4 is Ala, Xaa5 is Ser, Xaa6 is Gly, and Xaa7 is Thr, or (b) SEQ ID NO: 29, wherein Xaa4 is Ser, Xaa5 is Ala, Xaa6 is Gly, and Xaa7 is Thr. <EOS>